Page 11 - Development Expense News Today

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations This Form 10-Q contains certain forward-looking statements including expectations of market... | May 5, 2023

FLORHAM PARK, N.J., May 04, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for... | May 4, 2023

The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and related notes, which appear elsewhere in this document, and with... | May 3, 2023

Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 GuidanceFull-year 2023 Top-line and Bot...

Strong progress toward three potential launches in 2023; Company reports first quarter 2023 results and reaffirms full year 2023 guidance First... | April 25, 2023

You should read the following discussion and analysis in conjunction with our financial statements, including the notes thereto contained in this Annual Report. This discussion contains... | April 17, 2023

Unless the context otherwise requires, all references in this section to the Company, we, us, or our refer to the business of Navitas and its subsidiaries. Throughout this section, unless otherwise... | April 3, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ... | March 31, 2023

Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diab...

Forward-Looking Statements In addition to historical information, the following Managements Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking... | March 30, 2023